| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3547 | Nadph Tetrasodium Salt | Electron donor and cofactor for many redox enzymes including nitric oxide synthetase |
|
| DCC3548 | Nafoxidine | Partial estrogen antagonist, inhibiting angiogenesis in some tissues by blocking the effects of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF), inducing oxidative stress, protein kinase C and calcium signaling |
|
| DCC3549 | Nag-26 | Novel potent full agonist for orexin receptor |
|
| DCC3550 | Nai003 | Novel highly selective antibacterial agent against Propionibacterium acnes |
|
| DCC3551 | Nalbuphine Hydrochloride | Mixed agonist/antagonist opioid modulator, binding with high affinity to the MOR and KOR, and having relatively low affinity for the DOR |
|
| DCC3552 | Naph-o2 | Novel fluorescent probe for detection of endogenously produced Naph-O2˙– in living cells and tissues |
|
| DCC3553 | Naphthyridine-azaquinolone | Novel repeat-structure-specific DNA ligand, specifically binding slipped-CAG DNA intermediates of expansion mutations |
|
| DCC3554 | Naphyrone Hydrochloride | Triple reuptake inhibitor |
|
| DCC3555 | Napi2b Inhibitor 15 | Novel Gut-Restricted Inhibitor of Intestinal Sodium-Dependent Phosphate Transport Protein 2b (NaPi2b) for the Treatment of Hyperphosphatemia |
|
| DCC3556 | Napitane Mesylate | Antagonist of alpha-2 adrenergic receptors and inhibitor of the neuronal uptake of norepinephrine |
|
| DCC3557 | Napsagatran | Inhibitor of extrinsic and intrinsic thrombin generation, inhibiting clot-bound and free (fluid-phase thrombin) |
|
| DCC3558 | N-arachidonoyl Taurine | Activator of the transient receptor potential vanilloid (TRPV) channels TRPV1 and TRPV4 |
|
| DCC3559 | Nargenicin | Natural DnaE1 blocker, inducing a DNA damage response in Mycobacterium tuberculosis (Mtb) and inhibiting growth by blocking the replicative DNA polymerase, DnaE1 |
|
| DCC3560 | Tylophorine | Potent suppressor of inducible nitric oxide synthase (iNOS; NOS II) |
|
| DCC3561 | Nav1.1-in-b | Novel selective NaV1.1 inhibitor, reducing visceral hypersensitivity |
|
| DCC3562 | Nav1.7 Blocker-13 | Novel selective blocker of NaV1.7 with little affinity for NaV 1.2, 1.3, or 1.6, being more potent at human vs guinea pig NaV1.7 |
|
| DCC3563 | Nav1.7 Blocker-24 | Potent and selective blocker of voltage-gated Nav1.7 sodium channels |
|
| DCC3564 | Nav1.7 Blocker-801 | Potent NaV1.7 blocker, being 5-10 fold more potent than NaV 1.2 and NaV 1.6 |
|
| DCC3565 | Navarixin | Novel CXC chemokine receptor 2 (CXCR2) antagonist |
|
| DCC3566 | Naveglitazar | Dual peroxisome proliferator-activated receptor gamma and alpha (PPARgamma and PPARalpha) agonist |
|
| DCC3567 | Naxifylline | Potent and selective A1 adenosine receptor antagonist |
|
| DCC3568 | Nb-360 | Biological Active Reagents |
|
| DCC3569 | Nb-caged Tyrosine Hydrochloride | L-Tyrosine caged with photosensitive ortho-nitrobenzyl side chain |
|
| DCC3570 | Nbd-09027 | Novel HIV-1 entry inhibitor |
|
| DCC3571 | Nbd-10007 | Novel HIV-1 entry inhibitor |
|
| DCC3572 | Nbd-14136 | Novel CD4-mimetic HIV-1 entry inhibitor |
|
| DCC3573 | N-bn-thaz Fumarate | Potent agonist of the human 5-HT2A and 5-HT2C receptors |
|
| DCC3574 | Nboh-2c-cn Hydrochloride | Potent and selective 5-HT2A receptor agonist |
|
| DCC3575 | Nbti-5463 | Novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy |
|
| DCC3576 | nc00094221 | M. tuberculosis Dihydrofolate Reductase Inhibitor |
|
